
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Pediatric dermatologist Elaine Siegfried, M.D., says that, about 80 percent of the time, she has to treat patients with drugs that have no FDA-approved indication or have never been formally studied in children.